Innate Pharma SA
IPHA· Nasdaq
IPHAInnate Pharma SA
Who holds Innate Pharma SA, from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Lion Point Capital, LP | 81.2K | ±0% | $149.3K | 0.7% | Aug 14, 2026 |
| Morgan Stanley | 43.5K | ±0% | $80.1K | 0% | Aug 13, 2026 |
| SmartHarvest Portfolios, LLC | 23.8K | New | $43.7K | 0.1% | Aug 4, 2026 |
| XTX Topco Ltd | 15.1K | New | $27.8K | 0.1% | Aug 14, 2026 |
| Citadel Advisors LLC | 12.4K | New | $22.9K | 0% | Sep 2, 2026 |
| Jane Street Group, LLC | 10.3K | −76.2% | $19K | 0% | Aug 14, 2026 |
| Rhumbline Advisers | 4.7K | −0.3% | $8.7K | 0% | Aug 12, 2026 |
| UBS Group AG | 1.4K | +58.3% | $2.5K | 0% | Aug 13, 2026 |
| Farther Finance Advisors, LLC | 21 | +110.0% | $38 | 0% | Jul 17, 2026 |
| GAMMA Investing LLC | 9 | −96.3% | $17 | 0% | Jul 7, 2026 |
